精彩内容药物控制是目前治疗糖尿病的主要方式。米内网数据显示,近年来中国公立医疗机构终端糖尿病化药销售额呈上涨态势,2024年接近300亿元(+11.19%),2025年前三季度超过230亿元(+3.79%);从集团排名看,华东医药、恒瑞医药亮眼;产品排名中,国采品种霸榜,5大品种涨逾100%;6个品种满足国采入围门槛,又有哪些会被纳入第十二批国采?糖尿病化药300亿市场!华东、恒瑞亮了中国是糖尿病...
Source Link精彩内容药物控制是目前治疗糖尿病的主要方式。米内网数据显示,近年来中国公立医疗机构终端糖尿病化药销售额呈上涨态势,2024年接近300亿元(+11.19%),2025年前三季度超过230亿元(+3.79%);从集团排名看,华东医药、恒瑞医药亮眼;产品排名中,国采品种霸榜,5大品种涨逾100%;6个品种满足国采入围门槛,又有哪些会被纳入第十二批国采?糖尿病化药300亿市场!华东、恒瑞亮了中国是糖尿病...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.